Prospective Evaluation of Hot Flashes During Treatment With Parenteral Estrogen or Complete Androgen Ablation for Metastatic Carcinoma of the Prostate

Spetz, Anna-Clara; Hammar, Mats; Lindberg, B; Spångberg, Anders; Varenhorst, Eberhard

doi:10.1016/s0022-5347(05)65973-3

Cited by 63 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large randomized study in men with M1 prostate cancer, for example, demonstrated that the incidence of hot flashes associated with high-dose parenteral estrogen was 30%, compared with a 74% incidence of hot flashes in men receiving CAB (P<0.001) [18]. Another randomized study in men with M0 prostate cancer found a lower incidence of hot flashes in men receiving bicalutamide monotherapy compared with castration [8].…”

Section: Hot Flashesmentioning

confidence: 99%

Complications of androgen deprivation therapy in men with prostate cancer

Chen

Petrylak

2004

Curr Oncol Rep

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is indicated for the treatment of metastatic prostate cancer and locally advanced disease. In addition to sexual side effects, long-term ADT results in several other changes, including hot flashes; gynecomastia; changes in body composition, metabolism, and the cardiovascular system; osteoporosis; anemia; psychiatric and cognitive problems; and fatigue and diminished quality of life. This review discusses these complications of ADT and treatments aimed at reducing them. It is important for clinicians to anticipate these effects and to initiate measures to prevent or minimize them in order to maintain quality of life in prostate cancer survivors.

show abstract

Section: Hot Flashesmentioning

confidence: 99%

Complications of androgen deprivation therapy in men with prostate cancer

Chen

Petrylak

2004

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Although most men do not require treatment, a prospective trial found that 11.3% of patients found hot flashes distressing enough to negatively affect their quality of life. 9 Various pharmaceuticals have been used for those men requiring therapy with varying degrees of success. Cyproterone acetate, medroxyprogesterone acetate and clonidine have been reported to be helpful in some patients, although not without the cost of inducing their own side effects.…”

Section: Discussionmentioning

confidence: 99%

“…7,8 One study suggested that the frequency and severity of vasomotor symptoms were most prominent during the first year after castration. 9 In contrary to postmenopausal hot flashes that usually disappear after 2 to 5 years, for men after orchidectomy or receiving continuous GnRH therapy, vasomotor symptoms usually persist. The duration of the symptoms may therefore be quite long, given that many more men are receiving these agents at an earlier stage in their disease.…”

Section: Introductionmentioning

confidence: 99%

Dong Quai (angelica sinensis) in the treatment of hot flashes for men on androgen deprivation therapy: results of a randomized double-blind placebo controlled trial

Al-Bareeq

Ray

Nott

et al. 2013

CUAJ

View full text Add to dashboard Cite

Objective: To determine whether Dong Quai, a Chinese herbal compound purported to be efficacious in treating menopausal vasomotor symptoms, has a therapeutic benefit in treating hot flashes among prostate cancer patients receiving androgen deprivation therapy. Methods:A randomized double-blind placebo controlled trial was conducted involving 22 men receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer with bothersome hot flashes. After recording a baseline log of the frequency, duration and severity of daily hot flashes, patients were randomly assigned in a 1:1 ratio to receive daily placebo or Dong Quai for 3 months. Vasomotor and adverse events were recorded daily. Blood work including serum prostate-specific antigen (PSA), international normalized ratio of prothrombin time and partial thromoboplastin time were recorded at baseline and at the termination of the study.Results: Seventeen of the 22 patients enrolled completed the trial.Baseline vasomotor duration and severity were equivalent between the groups, however the number of hot flashes were significantly more in the Dong Quai group (p = 0.02). With respect to the change in number of hot flashes per day, there was a slight decrease in the mean number among the Dong Quai group which was insignificant. The absolute change and average percentage change in perceived hot flash severity was similar in both groups. There was no significant decrease in the duration of the hot flashes between the 2 groups. Disease progression based on either PSA increase or change in digital rectal exam was not observed in any patient. Conclusion:In this small pilot study, there were no significant differences in the severity, frequency or duration of hot flashes among men receiving placebo or Dong Quai.Can Urol Assoc J 2010;4(1):49-53 RésuméIntroduction : Nous avons cherché à déterminer si le Dong Quai (Angelica sylvestris chinensis ou angélique chinoise), une plante médicinale chinoise censée être efficace dans le traitement des symptômes vasomoteurs liés à la ménopause, procure des bienfaits thérapeutiques aux patients atteints de cancer de la prostate présentant des bouffées vasomotrices pendant un traitement antiandrogène.Méthodologie : On a mené un essai randomisé à double insu et contrôlé par placebo auprès de 22 hommes recevant un agoniste de l'hormone de libération de l'hormone lutéinisante (LHRH) pour le traitement d'un cancer de la prostate et présentant des bouffées vasomotrices incommodantes. Après avoir noté au départ la fréquence, la durée et la gravité des épisodes quotidiens de bouffées vasomotrices, on a réparti les patients aléatoirement selon un rapport de 1:1 pour recevoir chaque jour un placebo ou du Dong Quai pendant 3 mois. Les effets vasomoteurs et les réac-tions indésirables ont été notés chaque jour. Des analyses sanguines comprenant le taux sérique d'APS et le rapport international normalisé du temps de Quick et du temps de thromboplastine partielle ont été effectuées au départ et à la fin de l'étude.Résultats : Dix...

show abstract

“…Spetz et al performed a prospective analysis comparing the incidence of hot flashes in men receiving CAB to that in men receiving estrogen therapy for treatment of PC. 52 In this study, in 915 patients with metastatic disease, 458 were treated with polyestradiol phosphate and 457 patients received CAB. Of men receiving CAB, 74.3% reported hot flashes compared to 30.1% in men receiving estrogen therapy (P , 0.001).…”

Section: Vasomotor Symptoms "Hot Flashes"mentioning

confidence: 99%

Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art

Milecki¹

2010

CMAR

View full text Add to dashboard Cite

Androgen-deprivation therapy (ADT) is used routinely in combination with definitive external beam radiation therapy (EBRT) in patients with high-risk clinically localized or locally advanced disease. The combined treatment (ADT-EBRT) also seems to play a significant role in improving treatment results in the intermediate-risk group of prostate cancer patients. On the other hand, there is a growing body of evidence that treatment with ADT can be associated with serious and lifelong adverse events including osteoporosis, cardiovascular disease, diabetes, and many others. Almost all ADT adverse events are time dependant and tend to increase in severity with prolongation of hormonal manipulation. Therefore, it is crucial to clearly state the optimal schedule for ADT in combination with EBRT, that maintaining the positive effect on treatment efficacy would keep the adverse events risk at reasonable level. To achieve this goal, treatment schedule may have to be highly individualized on the basis of the patient-specific potential vulnerability to adverse events. In this study, the concise and evidence-based review of current literature concerning the general rationales for combining radiotherapy and hormonal therapy, its mechanism, treatment results, and toxicity profile is presented.

show abstract

Prospective Evaluation of Hot Flashes During Treatment With Parenteral Estrogen or Complete Androgen Ablation for Metastatic Carcinoma of the Prostate

Cited by 63 publications

References 19 publications

Complications of androgen deprivation therapy in men with prostate cancer

Complications of androgen deprivation therapy in men with prostate cancer

Dong Quai (angelica sinensis) in the treatment of hot flashes for men on androgen deprivation therapy: results of a randomized double-blind placebo controlled trial

Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art

Contact Info

Product

Resources

About